Yi Chen

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Venues

Signal transduction and targeted therapy

RSC medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Tao Zhang, Zilu Pan, Jing Gao, Qingqing Wu, Gang Bai, Yan Li, Linjiang Tong, Fang Feng, Mengzhen Lai, Yingqiang Liu, Peiran Song, Yi Ning, Haotian Tang, Wen Luo, Yi Chen, Yan Fang, Hui Zhang, Qiupei Liu, Yudi Zhang, Hua Wang, Zhiwei Chen, Yi Chen, Meiyu Geng, Hongbin Ji, Guilong Zhao, Hu Zhou, Jian Ding, Hua Xie
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation. Signal transduction and targeted therapy 9 (1) (2024)
Lihui Duo, Yi Chen, Qiupei Liu, Zhangyi Ma, Amin Farjudian, Wan Yong Ho, Sze Shin Low, Jianfeng Ren, Jonathan D Hirst, Hua Xie, Bencan Tang
Discovery of novel SOS1 inhibitors using machine learning. RSC medicinal chemistry 15 (4) (2024)
Lihui Duo, Yi Chen, Qiupei Liu, Zhangyi Ma, Amin Farjudian, Wan Yong Ho, Sze Shin Low, Jianfeng Ren, Jonathan D Hirst, Hua Xie, Bencan Tang
Discovery of novel SOS1 inhibitors using machine learning. RSC medicinal chemistry 15 (4) (2024)
Tao Zhang, Zilu Pan, Jing Gao, Qingqing Wu, Gang Bai, Yan Li, Linjiang Tong, Fang Feng, Mengzhen Lai, Yingqiang Liu, Peiran Song, Yi Ning, Haotian Tang, Wen Luo, Yi Chen, Yan Fang, Hui Zhang, Qiupei Liu, Yudi Zhang, Hua Wang, Zhiwei Chen, Yi Chen, Meiyu Geng, Hongbin Ji, Guilong Zhao, Hu Zhou, Jian Ding, Hua Xie
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation. Signal transduction and targeted therapy 9 (1) (2024)
Tao Zhang, Zilu Pan, Jing Gao, Qingqing Wu, Gang Bai, Yan Li, Linjiang Tong, Fang Feng, Mengzhen Lai, Yingqiang Liu, Peiran Song, Yi Ning, Haotian Tang, Wen Luo, Yi Chen, Yan Fang, Hui Zhang, Qiupei Liu, Yudi Zhang, Hua Wang, Zhiwei Chen, Yi Chen, Meiyu Geng, Hongbin Ji, Guilong Zhao, Hu Zhou, Jian Ding, Hua Xie
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation. Signal transduction and targeted therapy 9 (1) (2024)

Yi Chen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yi Chen